Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Large B-Cell, Diffuse 7Prostatic Neoplasms 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Melanoma 2Down Syndrome 2Carcinoma, Merkel Cell 2Carcinoma, Basal Cell 2Plasmablastic Lymphoma 1Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Myeloid, Accelerated Phase 1HTLV-I Infections 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Blast Crisis 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Rituximab 13Cyclophosphamide 9Magnetic Resonance Spectroscopy 7Lenalidomide 7venetoclax 6obinutuzumab 5ibrutinib 5Specimen Handling 5fludarabine phosphate 4fludarabine 4Whole-Body Irradiation 4Prednisone 4CT-P10 4Biopsy 4zanubrutinib 3orelabrutinib 3Vincristine 3Mycophenolic Acid 3Cyclosporine 3polatuzumab vedotin 2pirtobrutinib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Doxorubicin 2Busulfan 2Bendamustine Hydrochloride 2voruciclib 1treosulfan 1tafasitamab 1prednylidene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × prednylidene × 90 days × Clear all
NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡